(n = 60). Cell cates were amined for expon of p53 using the monockoal antibody p53-240. 
Wild-type p53 protein is known to have a signcant role in mgulating cell growth and protecting against carcinogenesis (Hollstein, 1991; Kasten et al., 1991; Lane, 1992) . Accumulation of the protein in tissues and cells indicates loss of the tumour-suppressor function and may occur as a result of a mutation in the gene or as a result of post-translational modifications (Werness et al., 1990; Furihata, 1993) . The protein has been shown to be overexpressed by many tumours, including breast, colon, gastric, hepatocellular and transitional cell carcinoma (TCC) (Harris and Hollstein, 1993; Spruck et al., 1993) . Despite the widespread expression of abnormal levels of p53 in human tumours, little is known about the expression of the protein in dysplastic or premalignant conditions. Most studies have concentrated on the expression of the protein in frank carcinoma (Harris and Hollstein, 1993) or in normal tissues experimentally exposed to carcinogens (Petersn, 1993; Jones et al., 1994; Mothersill et al., 1994 (1992) , Habuchi et al. (1992) , Esrig et al. (1993) , Lipponen (1993) and Sarkis et al. (1993) have all correlated p53 overexpression with invasive phenotype and progression of TCC, but whether the p53 mutation occurs early or late in the process of progression is not clear. Recent evidence from our group shows induction in urotheial cultures of p53 overexpression by radiation and/or nitrosamines, which are both known carcnogenic agents for bladder. (Lane and Benchimol, 1990) . p53-240 is also a mouse monoclonal antibody; however, it can only be used on non-paraffin-embedded tissue and is specific for the stable conformation of the protein (Gannon et al., 1990) . None of the antibodies are capable of identifying 100% of tissues with a proven (SSCP) mutation (Lamkin et al., 1994) . Positive and immunocytochemical analysis was therefore taken to mean expression of the non-functional or stable form of the p53 protein'.
Binding of the pnrmary antibody was detected using the Vectastain ABC kit (Vector Laboratonres. Burlingame, CA, USA) with diaminobenzidine as the colour detection system (Hsu et al., 1981) . Cultures and sections were counterstained with Harris haematoxylin. p53-D07 was used as the primary antibody on all paraffin-embedded material. A paraffinembedded breast cancer specimen known to express p53 was used as a positive control. The HaCAT cell line, known to express mutant p53 owing to a mutation on one allele of chromosome 17 and a deletion on the other in the p53 region, was used as a positive control for p53-240. This antibody was used to detect p53 in formalin-fixed tissue cultures. Cultures or paraffin sections which had been treated with all reagents, except the primary antibody, served as negative controls for both antibodies. Representative cultures were screened using an anti-cytokeratin antibody (pancytokeratin, Amersham, UK) to confirm that the cultured cells were epithelial rather than stromal.
Quantification and statistical analysis Growth was measured after 14 days in tissue culture by determining the number of 1 mm2 units covered by the outgrowth (excluding the original explant). The total cell number was determined by calculating the mean cell number in ten random 1 mm2 areas and multiplying this by the area of the outgrowth measured in mm-. Differential counts to determine the percentage postive cells were made by counting positive cells and total cell numbers along transects drawn across the outgrowth. By using percentage positive as opposed to total positive, it was possible to compare cultures from patients with different growth.
Results are presented as the cell number in each tissue culture after 14 days and the percentage of positive cells in each culture, with the standard error of the mean (s.e.m.) in parentheses. Each measurement was repeated on at least three (normally five) replicate cultures from each patient.
Results
Figure la shows the typical appearance of a 14-day-old urothelial culture with low (<5% of cells) p53 expression. Figure 2 shows the total cell number present in tissue cultures from each patient after 14 days. for both normal urothelial specimens obtained from patients with transitional cell carcinoma (n = 11) and those obtained from tumour-free patients (n = 60).
There is considerable variation between individual patients within each group. The mean number of cells per tissue culture for tumour-free patients was 4.28 ± 0.5 x I0W.
The mean number of cells for normal urothelial cultures from patients with transitional cell carcinomas was 8.67 ± 1.6 x 104. This difference in cell growth was found to be significant (P< 0.0005). The mean standard error with replicate cultures from the same patient was 3.8 ± 0.210%. A subgroup of tumour-free patients was found to express > 5% cells positive for p53 following tissue culture. These were shown to be statistical outliers using Grubb's test. The mean percentage positive p53 cells for patients in this subgroup of tumour-free patients was 50.7 ± 6.8%. This did not p53 ** i ndhuio cub Figure 4) . All specimens were initially evaluated for p53 expression using the p53-D07 antibody on paraffin-embedded tissue. None of the specimens from tumour-free patients were found to express p53 prior to tissue culture. Paraffin-embedded specimens of all normal urothelial specimens from TCC patients were also examined for p53 expression prior to tissue culture. The mean percentage positive p53 cells for normal urothelial samples from patients with TCC was 28.2 ± 6.1%. This expression was compared with that found following cell culture of specimens from the same patients in a paired Student t-test and was not found to differ significantly (P = 0.1916). Sections from 22 paraffin-embedded, muscleinvasive bladder cancers were also assessed for p53 expression using the p53-D07 antibody. These results are shown in Figure 5 and the expression of p53 in cultured normal urothelial specimens from patients with TCC is shown for comparison. The mean percentage positive cells for this group was 34.1 ± 3.8%. The expression of p53 in this group of tumours did not differ significantly from cultures of normal urothelium from patients with bladder carcinoma (P = 0.2632) or from paraffin-embedded specimens of normal urothelium from TCC patients (P = 0.398).
Eiscussion p53 has been identified as having a pivotal role in human carcinogenesis (Harris and Hollstein, 1993) . This study was aimed at confirming the overexpression of p53 in TCC observed by others Fujimoto et al., 1992) and determining if this overexpression of p53 could also be found in normal urothelium from patients with TCC. This finding would support an early involvement of p53 malfinction in premalignant urothelium and a 'field change' model for TCC. The results for staining of 22 invasive tumours with p53-D07 are similar to those of Wright et al. (1991) , who found that 64% (n = 33) of invasive tumours stained moderately or strongly positive with PAb 240 or PAb 1801. The use of an arbitrary scale for staining intensity in Wright's study prevents a direct comparison with our results.
p53-D07 was used to stain for p53 in the studies of paraffinembedded invasive TCC and normal urothelium prior to culture. This antibody detects both wild and mutant conformations of the protein; however, expression in paraffinembedded tissue is thought to be exclusively due to the mutated conformation of the protein (Lane and Benchimol, 1990 ). p53 overexpression in TCC has been shown to arise from genetic mutation rather than post-translational effects. The status of p53 protein expression in premalgnant urothelium is unclear but, given the current views on the role of p53 control of growth, DNA damage response and apoptosis (reviewed in Cohen, 1993) , it would seem logical that alterations in p53 protein function as opposed to underlying gene sequence could be expected at an early stage of car-
cinogenesis.
The results presented in this paper inicate that p53 overexpression is found in normal urothelium in patients with invasive TCC. Since specimens were taken from sites remote from the carcinoma (usually the ureters from cystectomy patients) and screened histologically for evidence of carcinoma or dysplasia, it is unlikely that the observed expression of p53 was due to the inadvertent inclusion of malignant cells in the explant specimen. The results, therefore, strongly support a field change model for TCC rather than a clonal model since it is hard to conceive of successful implantation of malignant tumour clones throughout every area of the urothelium accounting for 20-50% of cells in those areas, without then having any histologically recognisable or phenotypic changes. Specimens of normal urothelium from patients with invasive TCC were assessed for expression of p53 with both p53-D07, in intact tissue, and p53-240 following cell culture of specimens. While the expression of the protein was substantially higher following cell culture (mean percentage positive cells 46.4% vs 28.2%), this difference was not significant when analysed using a paired Student t-test . A similar association between abnormal p53 expression and dysplasia has been made in colonic adenomas; however, the protein was observed in focal areas of dysplasia rather than throughout the adenoma (Kawasaki et al., 1992 
